NovaBay Pharmaceuticals, Inc. http://www.novabaypharma.com a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, will present at the New York Society of Security Analysts’ (“NYSSA”) 11th Annual Biotech/Specialty Pharma Conference held at the NYSSA’s headquarters in New York City on Tuesday, December 11 at 3:30PM/EST. The live PowerPoint presentation with streaming video will be webcast and archived for one year at:
http://investor.shareholder.com/media/eventdetail.cfm?eventid=47195&CompanyID=NBY&e=1&mediaKey=79860443FCCAECCD93F3C3F9401CFB25 Jack O’Reilly, NovaBay’s SVP, Corporate Development and Chief Financial Officer, will provide an overview of the company’s clinical development programs and the status of its licensing agreements with affiliates of Alcon, Inc. (NYSE: ACL) and Kinetic Concepts, Inc. (NYSE:KCI). Mr. O’Reilly will also highlight NovaBay’s recently reported positive Phase I safety results for its lead Aganocide® compound, NVC-422, a novel non-antibiotic anti-infective that has shown potent in vitro activity against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
California based NovaBay recently closed an initial public offering (IPO) of common stock on October 31, 2007, and is dually listed on the American Stock Exchange and the Toronto Stock Exchange under the symbol “NBY.”
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial, fungal and viral infections, including methicillin-resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in woundcare applications.
NovaBay(TM), Aganocide® and NeutroPhase(TM) are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
For more information visit the company’s website at www.novabaypharma.com
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Rachel Colgate / Erica Ruderman
Janet Vasquez / Susan Morgenbesser